{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T16:39:27Z","timestamp":1764002367321,"version":"3.37.3"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2020,7,24]],"date-time":"2020-07-24T00:00:00Z","timestamp":1595548800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,7,24]],"date-time":"2020-07-24T00:00:00Z","timestamp":1595548800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Colorectal Dis"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1007\/s00384-020-03703-x","type":"journal-article","created":{"date-parts":[[2020,7,24]],"date-time":"2020-07-24T11:02:36Z","timestamp":1595588556000},"page":"2113-2116","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Efficacy of biosimilar infliximab CT-P13 among inpatients with severe steroid-refractory colitis"],"prefix":"10.1007","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7954-0699","authenticated-orcid":false,"given":"Jacob E.","family":"Ollech","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inessa","family":"Normatov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noam","family":"Peleg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sushila R.","family":"Dalal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joel","family":"Pekow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dejan","family":"Micic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Russel D.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David T.","family":"Rubin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Sakuraba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,7,24]]},"reference":[{"issue":"4947","key":"3703_CR1","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1136\/bmj.2.4947.1041","volume":"2","author":"SC Truelove","year":"1955","unstructured":"Truelove SC, Witts LJ (1955) Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J 2(4947):1041\u20131048","journal-title":"Br Med J"},{"issue":"4","key":"3703_CR2","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.crohns.2010.02.001","volume":"4","author":"LC Dinesen","year":"2010","unstructured":"Dinesen LC, Walsh AJ, Protic MN, Heap G, Cummings F, Warren BF, George B, Mortensen NJM, Travis SPL (2010) The pattern and outcome of acute severe colitis. J Crohns Colitis 4(4):431\u2013437","journal-title":"J Crohns Colitis"},{"issue":"7","key":"3703_CR3","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1093\/ecco-jcc\/jjx009","volume":"11","author":"M Harbord","year":"2017","unstructured":"Harbord M, Eliakim R, Bettenworth D, Karmiris K, Katsanos K, Kopylov U, Kucharzik T, Moln\u00e1r T, Raine T, Sebastian S, de Sousa HT, Dignass A, Carbonnel F, for the European Crohn\u2019s and Colitis Organisation [ECCO] (2017) Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: Current Management. J Crohns Colitis 11(7):769\u2013784","journal-title":"J Crohns Colitis"},{"issue":"7","key":"3703_CR4","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1053\/j.gastro.2005.03.003","volume":"128","author":"G Jarnerot","year":"2005","unstructured":"Jarnerot G, Hertervig E, Friis-Liby I, Blomquist L, Karlen P, Granno C et al (2005) Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 128(7):1805\u20131811","journal-title":"Gastroenterology"},{"issue":"9857","key":"3703_CR5","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1016\/S0140-6736(12)61084-8","volume":"380","author":"D Laharie","year":"2012","unstructured":"Laharie D, Bourreille A, Branche J, Allez M, Bouhnik Y, Filippi J, Zerbib F, Savoye G, Nachury M, Moreau J, Delchier JC, Cosnes J, Ricart E, Dewit O, Lopez-Sanroman A, Dupas JL, Carbonnel F, Bommelaer G, Coffin B, Roblin X, van Assche G, Esteve M, F\u00e4rkkil\u00e4 M, Gisbert JP, Marteau P, Nahon S, de Vos M, Franchimont D, Mary JY, Colombel JF, L\u00e9mann M (2012) Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet 380(9857):1909\u20131915","journal-title":"Lancet"},{"issue":"1","key":"3703_CR6","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/S2468-1253(16)30003-6","volume":"1","author":"JG Williams","year":"2016","unstructured":"Williams JG, Alam MF, Alrubaiy L, Arnott I, Clement C, Cohen D, Gordon JN, Hawthorne AB, Hilton M, Hutchings HA, Jawhari AU, Longo M, Mansfield J, Morgan JM, Rapport F, Seagrove AC, Sebastian S, Shaw I, Travis SPL, Watkins A (2016) Infliximab versus ciclosporin for steroid-resistant acute severe ulcerative colitis (CONSTRUCT): a mixed methods, open-label, pragmatic randomised trial. Lancet Gastroenterol Hepatol 1(1):15\u201324","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"3703_CR7","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1002\/ibd.21680","volume":"18","author":"M Sjoberg","year":"2012","unstructured":"Sjoberg M, Walch A, Meshkat M, Gustavsson A, Jarnerot G, Vogelsang H et al (2012) Infliximab or cyclosporine as rescue therapy in hospitalized patients with steroid-refractory ulcerative colitis: a retrospective observational study. Inflamm Bowel Dis 18(2):212\u2013218","journal-title":"Inflamm Bowel Dis"},{"issue":"1","key":"3703_CR8","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1136\/gutjnl-2012-303376","volume":"63","author":"ME van der Valk","year":"2014","unstructured":"van der Valk ME, Mangen MJ, Leenders M, Dijkstra G, van Bodegraven AA, Fidder HH et al (2014) Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFalpha therapy: results from the COIN study. Gut 63(1):72\u201379","journal-title":"Gut"},{"issue":"4","key":"3703_CR9","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.biologicals.2016.03.006","volume":"44","author":"J Braun","year":"2016","unstructured":"Braun J, Kudrin A (2016) Switching to biosimilar infliximab (CT-P13): Evidence of clinical safety, effectiveness and impact on public health. Biologicals 44(4):257\u2013266","journal-title":"Biologicals"},{"key":"3703_CR10","unstructured":"European Medicines Agency (2017) Biosimilars in the EU- Information guide for healthcare professionals. Prepared jointly by the European Medicines Agency and the European Commission. [Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Leaflet\/2017\/05\/WC500226648.pdf"},{"key":"3703_CR11","unstructured":"FDA (2017) FDA\u2019s Overview of the Regulatory Guidance for the Development and Approval of Biosimilar Products in the US. [Available from: https:\/\/www.fda.gov\/downloads\/drugs\/developmentapprovalprocess\/howdrugsaredevelopedandapproved\/approvalapplications\/therapeuticbiologicapplications\/biosimilars\/ucm428732.pdf"},{"issue":"12","key":"3703_CR12","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1016\/j.cgh.2016.05.023","volume":"14","author":"S Ben-Horin","year":"2016","unstructured":"Ben-Horin S, Vande Casteele N, Schreiber S, Lakatos PL (2016) Biosimilars in inflammatory bowel disease: facts and fears of extrapolation. Clin Gastroenterol Hepatol 14(12):1685\u20131696","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"3703_CR13","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.biologicals.2014.05.005","volume":"42","author":"BG Feagan","year":"2014","unstructured":"Feagan BG, Choquette D, Ghosh S, Gladman DD, Ho V, Meibohm B, Zou G, Xu Z, Shankar G, Sealey DC, Russell AS (2014) The challenge of indication extrapolation for infliximab biosimilars. Biologicals 42(4):177\u2013183","journal-title":"Biologicals"},{"key":"3703_CR14","doi-asserted-by":"publisher","first-page":"5A","DOI":"10.1155\/2005\/269076","volume":"19 Suppl A","author":"MS Silverberg","year":"2005","unstructured":"Silverberg MS, Satsangi J, Ahmad T, Arnott ID, Bernstein CN, Brant SR et al (2005) Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 19 Suppl A:5A\u201336A","journal-title":"Can J Gastroenterol"},{"issue":"10086","key":"3703_CR15","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1016\/S0140-6736(17)30068-5","volume":"389","author":"KK Jorgensen","year":"2017","unstructured":"Jorgensen KK, Olsen IC, Goll GL, Lorentzen M, Bolstad N, Haavardsholm EA et al (2017) Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. Lancet 389(10086):2304\u20132316","journal-title":"Lancet"},{"issue":"Suppl 1","key":"3703_CR16","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1586\/17474124.2015.1091308","volume":"9","author":"J Jahnsen","year":"2015","unstructured":"Jahnsen J, Detlie TE, Vatn S, Ricanek P (2015) Biosimilar infliximab (CT-P13) in the treatment of inflammatory bowel disease: a Norwegian observational study. Expert Rev Gastroenterol Hepatol 9(Suppl 1):45\u201352","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"3","key":"3703_CR17","first-page":"169","volume":"12","author":"M Kaniewska","year":"2017","unstructured":"Kaniewska M, Moniuszko A, Rydzewska G (2017) The efficacy and safety of the biosimilar product (Inflectra((R))) compared to the reference drug (Remicade((R))) in rescue therapy in adult patients with ulcerative colitis. Prz Gastroenterol 12(3):169\u2013174","journal-title":"Prz Gastroenterol"}],"container-title":["International Journal of Colorectal Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00384-020-03703-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00384-020-03703-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00384-020-03703-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,23]],"date-time":"2021-07-23T23:38:44Z","timestamp":1627083524000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00384-020-03703-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,24]]},"references-count":17,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["3703"],"URL":"https:\/\/doi.org\/10.1007\/s00384-020-03703-x","relation":{},"ISSN":["0179-1958","1432-1262"],"issn-type":[{"type":"print","value":"0179-1958"},{"type":"electronic","value":"1432-1262"}],"subject":[],"published":{"date-parts":[[2020,7,24]]},"assertion":[{"value":"14 July 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"AS has received funding from AbbVie, Celltrion, and Takeda. SD has received grant support from Pfizer. JP has received grants from Takeda and Abbvie and serves as a consultant for Verastem. He was on the advisory board for Pfizer and Janssen. DTR is a consultant and has received grant support from Abbvie, Merck & Co., Janssen, Takeda, and Pfizer. RDC is a consultant at Abbvie, Celgene, Janssen, Pfizer, Takeda, and UCB Pharma.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}